异柠檬酸脱氢酶突变型急性髓系白血病的治疗靶点 - Suppr

Therapeutic targeting of isocitrate dehydrogenase mutant AML.

作者信息

Boddu Prajwal, Borthakur Gautam

机构信息

a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

出版信息

Expert Opin Investig Drugs. 2017 May;26(5):525-530. doi: 10.1080/13543784.2017.1317745. Epub 2017 Apr 19.

DOI:10.1080/13543784.2017.1317745

PMID:28388242

Abstract

摘要

相似文献

Therapeutic targeting of isocitrate dehydrogenase mutant AML.

Expert Opin Investig Drugs. 2017 May;26(5):525-530. doi: 10.1080/13543784.2017.1317745. Epub 2017 Apr 19.

SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):769-772. doi: 10.1016/j.clml.2018.10.007. Epub 2018 Oct 21.

Targeting isocitrate dehydrogenase (IDH) in cancer.

Discov Med. 2016 May;21(117):373-80.

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):460-5. doi: 10.1016/j.clml.2016.04.006. Epub 2016 May 5.

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.

Pharmacol Ther. 2017 Sep;177:123-128. doi: 10.1016/j.pharmthera.2017.03.003. Epub 2017 Mar 14.

Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.

Int J Mol Sci. 2024 Jul 19;25(14):7916. doi: 10.3390/ijms25147916.

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.

Curr Cancer Drug Targets. 2020;20(7):490-500. doi: 10.2174/1568009620666200424145622.

Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?

Eur J Haematol. 2016 Mar;96(3):211-21. doi: 10.1111/ejh.12690. Epub 2015 Nov 26.

Inhibition of mutant IDH1 in acute myeloid leukaemia.

Lancet Oncol. 2015 Jan;16(1):e9. doi: 10.1016/S1470-2045(14)71140-4. Epub 2014 Nov 28.

Targeting the Pathway in Acute Myeloid Leukemia.

Clin Cancer Res. 2018 Oct 15;24(20):4931-4936. doi: 10.1158/1078-0432.CCR-18-0536. Epub 2018 May 16.

引用本文的文献

Acute myeloid leukemia treatment outcomes with isocitrate dehydrogenase mutations: A systematic review and meta-analysis.

Medicine (Baltimore). 2024 Dec 6;103(49):e40565. doi: 10.1097/MD.0000000000040565.

Prediction of Tumor Development and Urine-Based Liquid Biopsy for Molecule-Targeted Therapy of Gliomas.

Genes (Basel). 2023 May 30;14(6):1201. doi: 10.3390/genes14061201.

Isocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patients.

Medeni Med J. 2023 Jun 20;38(2):102-110. doi: 10.4274/MMJ.galenos.2023.48768.

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.

Neuro Oncol. 2023 Feb 14;25(2):326-336. doi: 10.1093/neuonc/noac155.

Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China.

Acta Pharm Sin B. 2021 Jun;11(6):1526-1540. doi: 10.1016/j.apsb.2021.03.005. Epub 2021 Mar 9.

From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia.

Cancers (Basel). 2020 Feb 4;12(2):357. doi: 10.3390/cancers12020357.

Modulation of Mitochondrial Metabolic Reprogramming and Oxidative Stress to Overcome Chemoresistance in Cancer.

Biomolecules. 2020 Jan 14;10(1):135. doi: 10.3390/biom10010135.

Novel IDH1-Targeted Glioma Therapies.

CNS Drugs. 2019 Dec;33(12):1155-1166. doi: 10.1007/s40263-019-00684-6.

Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate.

Front Pharmacol. 2019 Jul 4;10:728. doi: 10.3389/fphar.2019.00728. eCollection 2019.

The Role of Forkhead Box Proteins in Acute Myeloid Leukemia.

Cancers (Basel). 2019 Jun 21;11(6):865. doi: 10.3390/cancers11060865.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Therapeutic targeting of isocitrate dehydrogenase mutant AML.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献